Laurus Labs Limited
LAURUSLABS.NS
National Stock Exchange of India1,394.30
INR
+11.70
- -
ISIN
INE947Q01028
CUSIP
Y2090Y105
Return %
Stock
S&P500
1Y
125.03
26.53
3Y
308.11
76.60
5Y
159.48
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Satyanarayana Chava
- Full Time Employees
- 6,007
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Serene Chambers Hyderabad India 500034
- IPO Date
- Dec 19, 2016
- Website
- lauruslabs.com
- Similar Companies
- Business
- Laurus Labs Limited is an India-based pharmaceutical and biotechnology company specializing in the development, manufacture, and sale of active pharmaceutical ingredients (APIs), generic finished dosage formulations (FDF), biologics, and contract development and manufacturing services (CDMO). Its core product portfolio includes APIs across therapeutic segments such as anti-retroviral, oncology including high-potent APIs, cardiovascular, central nervous system, anti-diabetic, gastroenterology, proton pump inhibitors, and ophthalmic small volume APIs. The company operates through four main divisions: Generics API, Generics FDF, Laurus Synthesis (custom synthesis and contract manufacturing), and Laurus Bio (biotechnology and biosimilars). Laurus Labs provides end-to-end integrated services from clinical phase drug development to commercial manufacturing, serving global pharmaceutical innovators with a focus on regulatory compliance and quality standards. Founded in 2005 and headquartered in Hyderabad, India, Laurus Labs operates multiple manufacturing and R&D facilities approved by global regulatory agencies including USFDA, WHO, EMA, and MHRA. In the last 1-2 years, Laurus Labs has made significant strategic investments and expansions including the commissioning of a second GMP-compliant CAR-T cell therapy manufacturing facility aimed at advancing its biotechnology capabilities by mid-2026, supported by a capital expenditure plan of approximately ₹470 crore. It has also expanded its integrated drug product capabilities and signed new long-term contract manufacturing agreements in generic finished dosage forms with a focus on high-asset turnover and attractive returns. The company prioritizes growth investments focused on API and CDMO segments with sustained expansions in fermentation technology and other cutting-edge science platforms. Laurus Labs has reinforced its commitment towards innovation in biotechnology, scaling up operations in genetic and cell therapy-focused segments while maintaining strong growth and diversification in its pharmaceutical API and formulations business internationally. The company employs over 6,500 people, including more than 1,050 scientists, and maintains a strong presence in global markets including the US, Europe, Japan, and emerging markets. Laurus Labs Limited's recent operational advancements include enhanced R&D capabilities, expanded commercial scale contract manufacturing services, and portfolio diversification into biopharmaceuticals, supporting its positioning as a vertically integrated pharmaceutical solutions provider. The company remains focused on leveraging complex chemistries, biocatalysis, flow chemistry, and peptide synthesis under its development pipeline, aimed to cater to evolving pharmaceutical industry needs. These developments align with Laurus Labs' vision to deliver comprehensive pharmaceutical solutions combining innovation, regulatory excellence, and operational scale, serving a broad spectrum of therapeutic areas on a global platform.